Back to Newsroom
Back to Newsroom

CBD Life Sciences, Inc. (CBDL) Reports: Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

Tuesday, 29 November 2022 08:00

CBD Life Sciences Inc.

SCOTTSDALE, AZ / ACCESSWIRE / November 29, 2022 / Today, CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces today that the first bill solely related to marijuana has been sent to POTUS after being approved by the U.S. House and Senate - an unfathomable feat a decade ago. Passed by unanimous consent, by the Senate, the marijuana-related bill signal times are changing and so are perceptions about marijuana and cannabidiol.

After years of battling to legalize marijuana for medical purposes, the H.R. 8454 - Medical Marijuana and Cannabidiol (CBD) Research Expansion Act marks a "historic breakthrough in addressing the federal government's failed and misguided prohibition of cannabis as a whole."

President & CEO Lisa Nelson states, "This will open up many opportunities for the company and this couldn't be a better time to enter the marijuana sector in a movement to take over the industry and become one of the top distributors in the United States!"

Per, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will:

Establish a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

In summary, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will allow a more streamlined approach to the application process for marijuana studies and will remove the strict barriers that have slowed down the process. Research on CBD and other potentially beneficial marijuana-derived substances will be based on sound science without regulatory hindrance. This Act is very significant due to it being the first legislation to unite opponents and proponents of cannabis legalization.

The number of benefits CBD has is tremendous! These benefits may help with behavioral/neurological complications such as ADD/ADHD, anxiety, autism, bipolar, OCD, PTSD, epilepsy, Parkinson's, osteoporosis, and ALS. CBD may also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn's, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension even our bodies way and ability to maintain homeostasis have all been said to receive help from CBD.

CBD Life Sciences Inc. will continue to keep its beloved shareholders up to date moving forward. More news to come.


LBC BIOSCIENCE'S Online Emporium

LBC Bioscience Inc. is well stocked already as it is with some very high-quality CBD offerings - all at very reasonable prices. Check out LBC Bioscience Inc's newest product offerings including its: 100MG CBD Bath Bombs in a variety of scents, Delta 8 Gummies, 1500 MG Premium Berry Drops, and a variety of all-new Skincare products. Or shop our top-selling products (based on order frequency) which include our CBD Pain Cream, CBD Oils and CBD Pet Treats.

Become a Distributor

Large Selection of Products (over 50 items and growing)

100% USA Made Products "organic & kosher."

All Products are THC-FREE (they contain 0.00% THC)

LBC Bioscience Inc. accepts: Visa, MasterCard, American Express, Discover etc.

Shareholders and interest holders may also stay current with LBC Bioscience Inc Updates:

LBC Bioscience Inc's Main Website at


About LBC Bioscience Inc.

LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products including CBD Drops, Gumballs, Honey Sticks, Pain Relief Creams, Anxiety & Sleep Supplements, Edibles, Coffee, Skincare Line, Pet Line, Tablets and more. LBC's products can be viewed and bought on the Company's website at

IR Contact

[email protected]

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking

SOURCE: CBD Life Sciences Inc.

Company Update
Back to newsroom
Back to Newsroom
Share by: